Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016

• Published in: BMC nephrology Vol. 21; no. 1; pp. 41 - 9
• Main Authors: Qin, Xuzhen, Tsoi, Man-Fung, Zhao, Xinyu, Zhang, Lin, Qi, Zhihong, Cheung, Bernard M. Y.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.02.2020; BioMed Central; BMC
• Subjects: Acute kidney injury; Age groups; Anemia; Antibiotics; Complications and side effects; Congestive heart failure; Creatinine; Data analysis; Diabetes mellitus; Diuretics; Drugs; Gender; Geriatrics; Health risk assessment; Heart failure; Hypertension; Infants; Kidney diseases; Kidneys; Meropenem; Methods; Mortality; Nephrology; Newborn babies; Patient monitoring; Patients; Piperacillin; Piperacillin-tazobactam; Prevention; Renal failure; Respiratory failure; Risk factors; Staphylococcus infections; Tazobactam; Vancomycin; Hong Kong, China; Hong Kong China; China; Acute kidney injury; Vancomycin

To study the incidence of vancomycin-associated acute kidney injury (VA-AKI) in Hong Kong and identify risk factors for VA-AKI. Patients with vancomycin prescription and blood level measurement in 2012-2016 were identified using the Hong Kong Hospital Authority Clinical Data Analysis and Reporting S...